---
schema_version: "secwatch.filing_event.v1"
accession: "0001493152-26-016865"
form_type: "8-K"
ticker: "VVOS"
cik: "0001716166"
company_name: "Vivos Therapeutics, Inc."
filed_at: "2026-04-15T23:59:59+00:00"
generated_at: "2026-05-15T06:08:10.456276+00:00"
event_type: "earnings"
sentiment: "neutral"
materiality_score: 0.7
calibrated_materiality_score: 0.7
confidence: "high"
source: SEC EDGAR
---

# Vivos Therapeutics FY2025 revenue up 16% to $17.5M; operating loss widens to $19.9M

## Summary
- FY2025 revenue $17.5M, +16% YoY from $15.0M; driven by sleep testing services and SCN acquisition.
- Operating loss $19.9M vs $11.2M in FY2024; expenses rose to $30.4M on SCN integration costs.
- Cash and equivalents $2.0M at Dec. 31, 2025; subsequent financing raised $6.8M in gross proceeds.
- Gross margin held at 60%; business pivoting from VIP enrollment to sleep provider acquisitions and alliances.
- Management targets achieving cash-flow-positive operations by end of 2026.

## SEC filing metadata
- accession: 0001493152-26-016865
- form_type: 8-K
- ticker: VVOS
- cik: 0001716166
- company_name: Vivos Therapeutics, Inc.
- filed_at: 2026-04-15T23:59:59+00:00
- event_type: earnings
- sentiment: neutral
- materiality_score: 0.7
- calibrated_materiality_score: 0.7
- confidence: high
- sec_items: 2.02, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1716166/000149315226016865/0001493152-26-016865-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1716166/000149315226016865/form8-k.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001493152-26-016865
- JSON: https://secwatch.observer/filing/0001493152-26-016865.json
- Plain text: https://secwatch.observer/filing/0001493152-26-016865.txt

## Key facts
- Earnings Releases
  Vivos Therapeutics, Inc. reported the full year ended December 31, 2025 results: revenue $17.5 million.
  - Period: the full year ended December 31, 2025
  - Revenue: $17.5 million
  - Result: reported results
  source text: Revenue was $17.5 million for the year ended December 31, 2025, compared to $15.0 million for the full year ended December 31, 2024, a year over year increase of 16%.
  evidence_url: https://www.sec.gov/Archives/edgar/data/1716166/000149315226016865/0001493152-26-016865-index.htm

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.